Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-Grown mini tumors could someday guide pancreatic cancer treatment

NCT ID NCT05351983

Knowledge-focused Sponsor: Prof. Dr. med. Dres. h.c. Jan Schmidt, MME Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether it is safe and possible to grow mini-tumors (organoids) from pancreatic cancer samples in the lab. 60 patients with pancreatic cancer provided tumor tissue during surgery or biopsy. The goal was to see if these organoids could be used to test different chemotherapy drugs. The results did not change the treatment patients received, but the information gathered may help doctors choose better treatments in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Sep 2022

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Written informed consent provided * Patients older than 18 years * Histologically- or cytologically-proven pancreatic ductal adenocarcinoma (PDAC) * Tumour lesion amenable for laparoscopic, surgical biopsy * Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2 * Radiologically measurable disease * Life expectancy \> 3 months * Absolute neutrophile count \>1500/microL, platelets \>100'000/microL * Serum creatinine \<1.5 times of the upper limit of normal or Clearance \>50ml/min (according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) Exclusion criteria: * Concomitant need for full anticoagulation that cannot be interrupted or bridged prior to tissue biopsy * ECOG PS \>2 * Heart failure (NYHA class III-IV) * Severe or uncontrolled concurrent illness * Myocardial infarction within the previous 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreas adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreas adenocarcinoma Pancreas cancer Pancreas neoplasm Pancreatic adenocarcinoma Pancreatic cancer Pancreatic neoplasms

Contacts and locations

Locations

  • Hirslanden Kliniks

    Zurich, Canton of Zurich, 8002, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.